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Abstract
Background: Epigenetic mechanisms such as DNA methylation and histone modifications are important regulators
of gene expression and are frequently involved in silencing tumor suppressor genes.
Methods: In order to identify genes that are epigenetically regulated in neuroblastoma tumors, we treated four
neuroblastoma cell lines with the demethylating agent 5-Aza-2’-deoxycytidine (5-Aza-dC) either separately or in
conjunction with the histone deacetylase inhibitor trichostatin A (TSA). Expression was analyzed using whole-
genome expression arrays to identify genes activated by the treatment. These data were then combined with data
from genome-wide DNA methylation arrays to identify candidate genes silenced in neuroblastoma due to DNA
methylation.
Results: We present eight genes (KRT19, PRKCDBP, SCNN1A, POU2F2, TGFBI, COL1A2, DHRS3 and DUSP23) that are
methylated in neuroblastoma, most of them not previously reported as such, some of which also distinguish
between biological subsets of neuroblastoma tumors. Differential methylation was observed for the genes SCNN1A
(p < 0.001), PRKCDBP (p < 0.001) and KRT19 (p < 0.01). Among these, the mRNA expression of KRT19 and PRKCDBP
was significantly lower in patients that have died from the disease compared with patients with no evidence of
disease (fold change -8.3, p = 0.01 for KRT19 and fold change -2.4, p = 0.04 for PRKCDBP).
Conclusions: In our study, a low methylation frequency of SCNN1A, PRKCDBP and KRT19 is significantly associated
with favorable outcome in neuroblastoma. It is likely that analysis of specific DNA methylation will be one of
several methods in future patient therapy stratification protocols for treatment of childhood neuroblastomas.
Background
Neuroblastoma (NB) is a pediatric tumor of the post-
ganglionic sympathetic nervous system that develops
from immature or de-differentiated neural crest-derived
cells. It is the most common extracranial pediatric solid
tumor, responsible for 15% of cancer deaths in child-
hood [1]. Much effort has been made to identify genes
involved in the initiation/progression of NB. Tumor
suppressor genes (TSGs) can be inactivated by muta-
tions or deletions. Only infrequent mutations have been
identified in neuroblastoma and homozygous deletions
a r er a r ee v e n t si np r i m a r yN Bt u m o r s .O n l yaf e wh a v e
been reported in single cases [2-6]. Another mechanism
for the inactivation of TSGs is epigenetic, where DNA
methylation is the most studied. Several genes have
been reported as being methylated in NB at different
frequencies; for example the RASSF1A gene on chromo-
s o m ea r m3 p[ 7 ] .W eh a v ep r e v i o u s l ya n a l y z e dt h e
methylation status of chromosome region 1p36 in NB, a
region that is often heterozygously deleted in this tumor
[8,9]. The regulation of gene expression also involves
several modifications of histones. Acetylation and deace-
tylation on histones H3 and H4 are regulated by histone
acetyltransferase (HAT) and histone deacetylase
(HDAC). One approach to identifying candidate genes
that are regulated epigenetically is to treat cancer cell
lines with DNA methyltransferase inhibitors and/or his-
tone deacetylase inhibitors, followed by an expression
microarray analysis to identify genes that are upregu-
lated by treatment. One advantage of this technique
over direct methylation analysis is that it identifies epi-
genetic changes that also lead to a change in gene
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that several genes that are not methylated turn out to be
positive for methylation, since these genes can be acti-
vated indirectly and not due to the demethylation of the
respective gene. In this study, we have therefore com-
bined a cell treatment study with a genome-wide DNA
methylation analysis performed using the Illumina
Human Methylation27 DNA analysis BeadChip to iden-
tify genes that are truly regulated by epigenetic mechan-
isms in NB cell lines and tumors. We selected a number
o ft h ei d e n t i f i e dg e n e sa n di n v e s t i g a t e dt h e mf u r t h e r ;
the selected genes were indeed methylated and the
methylation frequencies of some of them were able to
distinguish between different subgroups of NB tumors.
Results
The work flow of the analysis including samples used is
described in Figure 1.
Validity of methods
Several genes previously known to be epigenetically
regulated were identified in the 5-Aza-dC and/or TSA
expression microarray treatment experiment. ZMYND10
(BLU), THBS1 and SFN (14-3-3sigma)h a v ep r e v i o u s l y
been reported to be methylated in NB [10-12]. More-
over, imprinted genes (for example, NNAT and PEG3)
were detected, as expected. All these genes were also
identified as methylated by the Illumina Human Methy-
lation27 DNA analysis BeadChips analysis. Since the
methylation status of all these genes is already known,
they were not analyzed further. See additional file 1 and
2 for the number of genes affected in the treatments
and additional file 3 for lists of the affected genes. The
data from the Illumina Human Methylation27 DNA
analysis BeadChips have been validated elsewhere
(Carén et al, in manuscript).
The NB cell lines showed great heterogeneity in the
cell treatment experiments (additional file 4). The lar-
gest number of upregulated genes after 5-Aza-dC/TSA
treatment was found in SK-N-BE (1617 probes upregu-
lated >2-fold) followed by IMR-32 (1422), SK-N-AS
(1182) and SK-N-DZ (875). The same pattern was seen
after only 5-Aza-dC treatment (IMR-32, 591 probes
upregulated, SK-N-AS 334 and SK-N-DZ 84). The low
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Figure 1 Work flow of the analysis. The figure describes the work flow of the analyses, samples used for respective analysis and gives a
summary of all figures and additional files.
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Page 2 of 11number of genes upregulated by treatment in SK-N-DZ
is consistent with the finding that SK-N-DZ has the
lowest number of methylated CpG sites with a beta
value above 0.75 (above half the number as the other
cell lines).
Selection of candidate genes
Genes were chosen as candidates for epigenetic regula-
tion if they had a fold change of >2 between treated and
untreated cell lines in at least one cell line. The com-
mon set of genes that was affected by both treatments
w a sc o n s i d e r e dm o r el i k e l yt ob et r u et a r g e t so fe p i g e -
netic regulation and we therefore focused on this com-
mon set. Furthermore, genes that had no or only low
expression in the untreated cell lines and that were
affected by treatment, were considered as candidate
genes. These data were combined with the Illumina
methylation array data (Carén et al, in manuscript) and
genes that also had a methylation beta value of more
than 0.6 in primary NBs were selected. For the number
of genes identified in the different steps, see additional
file 2. The identified genes were examined for CpG
i s l a n d su s i n gt h eU C S Cg e n o m eb r o w s e ra n dC p G
island searcher. Ontology information was provided by
the arrays; genes with functions related to cancer were
selected. The gene lists were also used to search for
NCBI abstracts using PubMatrix (URL: http://pubma-
trix.grc.nia.nih.gov) with queries relating to neuroblas-
toma, methylation and tumorigenesis. After the
bioinformatic analysis, nine genes were selected for
further analysis, see Table 1 and additional file 5[13-37].
Verification of the array data with expression analysis
using real-time RT-PCR
The selected genes were analyzed in the same set and in
another set of NB cell lines treated with 5-Aza-dC and/
or TSA with real-time RT-PCR using TaqMan Technol-
ogy. In most cases, there was a good correlation
between the expression microarray data and the Taq-
Man data; when the gene was identified as upregulated
by the array, it was generally also upregulated in the
TaqMan analysis, although the magnitude of the values
was not the same. Moreover, the new set of NB cell
lines also showed upregulation of the genes after treat-
ment (see additional file 6).
Bisulfite sequencing and methylation-specific PCR
On the Illumina methylation arrays, the CpG sites can
be located inside or outside of the CpG islands of the
corresponding gene. In order to verify that the CpG site
analyzed with the array was indeed methylated, or to
ensure that, for the genes with the CpG sites outside
the CpG islands, the corresponding CpG island was also
methylated and to confirm that the surrounding CpG
sites were methylated, bisulfite sequencing assays were
designed. All genes were found to have methylated pro-
moter CpG islands. The bisulfite sequencing analysis
included DNA from NB cell lines, normal adrenal and
blood lymphocytes from healthy blood donors for all the
genes, as well as primary NB tumors (n = 13-34) for
three of the genes (SCNN1A, POU2F2 and COL1A2).
All the analyzed genes were unmethylated or showed
low methylation in the adrenal sample, as well as in the
blood lymphocyte samples. All the genes were methy-
lated in more than half of the cell lines (Figure 2). The
methylation beta value from the Illumina methylation
arrays was compared with the peak heights of the
sequencing electropherograms from bisulfite sequencing
of the genes where the CpG site analyzed by the methy-
lation array was inside of the PCR fragment analyzed by
BSP (TGFBI, PRKCDBP, DUSP23 and COL1A2). There
were good correlations between the methods.
Differential methylation analysis
In order to see whether the methylation also varied
among biologically different subgroups of NB, we com-
pared the methylation beta values from the Illumina
arrays with different patient variables. We compared
patients who are alive with no evidence of disease
(NED) five years after diagnosis (5-year overall survival;
OS) with those who were dead of disease (DOD),
known prognostic chromosomal aberrations such as 1p
deletion, MYCN amplification, 11q deletion and 17q
gain, age at diagnosis, as well as chromosomal profiles
obtained from array copy number data analysis [2]. Dif-
ferential methylation based on 5-year OS was seen for
the genes SCNN1A, PRKCDBP and KRT19 with a higher
methylation frequency found in tumors from patients
with an unfavorable outcome, see Figure 3A and
Table 2. For SCNN1A, PRKCDBP, KRT19, TGFBI and
DUSP23, significantly higher methylation frequencies
found in MYCN-amplified tumors, see Figure 3B and
Table 3.
The odds ratio (OR) for 5-year OS was calculated
using MYCN amplification, 1p deletion, 11q deletion,
17q gain or gene methylation as prognostic factors. The
OR was 5.7 for MYCN amplification (95% CI 1.7-19.1),
4.4 for 1p deletion (95% CI 1.4-13.6), 3.4 for 11q dele-
tion (95% CI 1.1-11.1) and 10.8 for 17q gain (95% CI
3.0-38.7). For gene methylation, the ORs are given for
one (1) standard deviation increase in beta units of
methylation. The OR for SCNN1A was 3.4 (95% CI 1.5-
7.3), for PRKCDBP 2.5 (95% CI 1.3-4.8) and for KRT19
2.5 (95% CI 1.2-5.0). As a prognostic tool, known factors
such as MYCN amplification predict the outcome of
70% of cases in our material correctly, 1p deletion 69%,
11q deletion 66% and 17q gain 74%. Using the estimated
logistic regression model and a cut-off at 50% risk, the
Carén et al. BMC Cancer 2011, 11:66
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PRKCDBP 76% and KRT19 64% of cases correctly.
Expression analysis with real-time RT-PCR
Real-time RT-PCR data of the eight genes was generated
from primary tumors, NB cell lines and control tissues
using custom-designed TLDA cards (Applied Biosys-
tems, Foster City, CA). All the genes were expressed in
all control tissues. SCNN1A expression was absent in
44% of the NB tumors analyzed, the other genes were
expressed in all tumors. The mRNA expression of the
genes KRT19, PRKCDBP and DUSP23 was significant
lower in patients that have died from disease compared
with patients with no evidence of disease (fold change
-8.3, p = 0.011, -2.4, p = 0.036 and -2.8, p = 0.017,
respectively; see additional file 7).
Discussion
In this study, we treated four NB cell lines with 5-
Aza-dC and/or TSA and analyzed the RNA with expres-
sion microarrays. Data from Illumina genome-wide
methylation arrays (Carén et al,i nm a n u s c r i p t )o f5 9
primary NB tumors were also used to identify genes
that were activated by treatment as well as being methy-
lated. Eight genes were selected as candidate genes for
epigenetic silencing and the data from the 5-Aza-dC
and/or TSA expression microarray were validated for
these genes with real-time RT-PCR in the same set of
cell lines, as well as in five additional NB cell lines. The
results from the microarray and the real-time RT-PCR
analysis was generally in accordance and most of the
additional five cell lines showed the same pattern of
gene activation after 5-Aza-dC and/or TSA treatment
(see additional file 6). Bisulfite sequencing was per-
formed to validate the methylation status in the respec-
tive promoter CpG islands; all the eight genes were
indeed methylated in the region surrounding the tran-
scription start sites. Differential methylation beta values
from the Illumina methylation arrays were analyzed to
explore if the beta values of the eight genes could be
used to distinguish different subsets of NB. See table 2
for various tumor characteristics that could be distin-
guished using methylation beta values of different genes.
A high beta value was generally associated with unfavor-
able characteristics. For example, the beta values of
SCNN1A, PRKCDBP and KRT19 could distinguish
between patients with a 5-year OS from those that have
died of the disease. The beta values of these three genes
as well as for TGFBI and DUSP23 were also correlated
with MYCN amplification. TGFBI expression has
previously been shown to be inversely correlated to
MYCN amplification [14]. Our data suggest that DNA
methylation could be a factor that is responsible for
this. Real-time RT-PCR analysis of the eight genes was
also performed. Gene expression could be detected in
most of the NB tumors and in all control tissues
(SCNN1A was only expressed in 56% of NB tumors).
The mRNA expression of KRT19, PRKCDBP and
DUSP23 was significantly lower in tumors from patients
that have died from the disease compared with patients
Table 1 Information of the genes studied in relation to tumorigenesis.
Symbol Chr Role Methylated in other cancers Comment
DHRS3 1p36 Short-chain
dehydrogenases/
reductase
Melanoma cell lines [17] Enzyme involved in retinol metabolism. Putative TSG, crucial for the
development of neural crest cells, located in NB SRO of deletions
[16,18]. Recently reported as one of three candidate genes that
were significantly overexpressed in favorable NB [19].
DUSP23 1q23 Dual-specificity
protein
phosphatase
Role in mitogenic signalling & cell cycle control. Fetal expression -
possible role in early development [25,26].
TGFBI 5q31 Extracellular matrix
protein
Leukemia, renal cell-, lung-, esophageal
cancer [24]
Involved in cell adhesion and tumorigenesis [14,15]. Reduces
proliferation and invasion in vitro and in vivo in NB. The mRNA
expression of TGFBI is inversely correlated to MYCN expression in
NB [19].
COL1A2 7q22 Type I collagen Medulloblastoma, colorectal- breast-
and bladder cancer, melanoma
[13,21,23,29]
Tumors that secrete the gene have low tumorigeneic potential [27].
PRKCDBP 11p15 Protein kinase
binding
Breast-, lung-, ovarian- and gastric
cancer, glioblastoma multiforme
[20,31,35-37]
Also called hSRBC. Putative TSG.
SCNN1A 12p13 Ion transport Breast cancer [22] Contributes to methylator phenotype in breast cancer [22].
POU2F2 19q13 Transcription
factor
Regulator of neuronal differentiation [34].
KRT19 17q21 Intermediate
filament protein
Renal cell carcinoma [30] Involved in cell migration, invasion and metastasis [28]. Used as
biomarker for detection of disseminated tumor cells [33]. Low
expression in MNA NB [32].
TSG, tumor suppressor gene; NB, neuroblastoma; SRO, shortest region of overlap; MNA, MYCN-amplified.
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value of the gene KRT19 (CpG site cg11462865) was
correlated (by Spearman correlation; correlation -0.54, p
= 0.002) with the mRNA expression in paired samples.
Also for DHRS3 a correlation was detected (cg01346152,
correlation -0.42, p = 0.02). The other genes did not
show this paired sample correlation, indicating that the
analyzed CpG sites in these genes are located in regions
that are not important for gene regulation. There are
also technical explanations for this. For example, since
the DNA and RNA have been extracted using different
samples of the same tumor the heterogeneity of the
tumor could explain that correlations are not seen since
it is not the identical sample that is analyzed. The fact
that correlations in DNA methylation and mRNA
expression are not seen for all the genes may also reflect
the difficulties involved in analyzing RNA; RNA is much
more unstable and degrades far more easily than DNA.
In contrast, the methylation of DNA is a robust, stable
procedure and much easier to measure. This could also
explain why DNA methylation is far more closely
correlated to various tumor characteristics than gene
expression (see Table 2 and additional file 7).
The three identified genes with differential methylation
(SCNN1A, PRKCDBP and KRT19) have all previously
been reported as methylated in different forms of tumors.
SCNN1A is an ion transport gene that has been reported
to be one of six genes that contribute to a hypermethylator
phenotype that is seen in a subset of breast cancer cell
lines and primary tumors [22]. Hypermethylation of the
putative tumor suppressor gene PRKCDBP (also known as
hSRBC) has been reported in several different tumors
(Table 1). Stable expression of PRKCDBP has been shown
to induce cell cycle arrest in the G1 phase as well as apop-
tosis, and suppress cellular growth in vitro and in xeno-
graft tumors by enhancing the protein stability of p53 and
the expression of p53 target genes [20]. KRT19 (CK19)
encodes an element of the cytoskeleton and shows fre-
quent DNA methylation in renal cell carcinoma (RCC)
cell lines and primary RCC, without methylation in normal
renal tissue [38]. KRT19 mRNA has also been reported to
be downregulated in squamous cell carcinoma (SCC) of
C
A
SCNN1A KRT19
B
M
U
Figure 2 Bisulfite sequencing analysis. (A) Summary of bisulfite sequencing analysis of methylation status in cell lines and control tissues of
the selected genes. (B) Methylation-specific PCR analysis of DHRS3. M, methylation-specific reaction; U, non-methylation-specific reaction. Samples
from left to right: SK-N-AS, SK-N-BE(2), SK-N-DZ, SK-N-FI, Kelly, NB69, IMR-32, SK-N-SH, SH-SY-5Y, adrenal, blood lymphocytes (3 samples),
unmethylated control, methylated control and negative PCR control. Most of the NB cell lines are partially methylated, as they show both
methylated and unmethylated products. NB69 is although completely methylated, and SK-N-DZ and SK-N-SH unmethylated (although weak
methylated bands can be detected by careful inspection, which could reflect a low level of methylation in these samples). (C) Examples of
bisulfite sequencing of SCNN1A and KRT19. Cytosines/tymines in the CpG dinucleotide are underlined. C in the sequence indicates methylated
CpG sites and T unmethylated. SCNN1A, top sequence IMR-32, bottom adrenal; KRT19, top sequence SH-SY-5Y and bottom, blood lymphocytes.
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was shown to decrease SCC invasiveness by diminishing
migratory capability [39].
Conclusions
Based on our data, SCNN1A, PRKCDBP and KRT19 are
the best candidates for further analysis in NB. The
methylation frequencies of all of these genes can sepa-
rate tumors from patients with no evidence of disease
f r o mt h o s et h a th a v ed i e df r o md i s e a s e .T h em R N A
expression of KRT19 and PRKCDBP is also significantly
different in tumors from these two groups of patients. It
would therefore be very interesting to explore the func-
tions of these genes in relation to NB development/pro-
gression and their use as potential biomarkers for
prognostic use.
The number of tumors analyzed in this study was fairly
small (n = 59) and the findings that the methylation
pattern of the genes mentioned here is associated with
different biological subgroups of NB need to be verified
in a larger number of tumors. Nevertheless, as a prognos-
tic tool, the methylation of most of the genes presented
here is just as good or better as the known prognostic
risk factors, such as 1p deletion, MYCN amplification,
11q deletion and 17q gain, when it comes to predicting
accurate outcome in this set of tumors. In addition, this
study uses a technique that has not previously been used
for this tumor and it highlights genes with interesting
functions that have not previously been reported as
methylated in NB. Stable biomarkers as DNA methyla-
tion are likely to be important in the risk stratification of
patients with NB in the future. It is essential to make the
best possible prognosis in order to cure as many patients
as possible, as well as to avoid unnecessary treatment
which can lead to severe side-effects in this group of
young patients.
p<0.001
SCNN1A
NED DOD
KRT19
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NED DOD
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PRKCDBP
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Num 
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17q-
gain
Other 
segm.
Num 
only
A
B
Figure 3 Differential methylation analysis. (A) Analysis of differences in methylation beta values from patients with no evidence of disease
(NED) compared to those with an adverse outcome (DOD) for the most statistically significant genes. One of the CpG sites from the Illumina
methylation array is shown. Box plot explanation; upper and lower hinges of the box represent the 75th percentile and 25th percentile
respectively; whiskers indicate the highest and lowest values that are not outliers or extreme values; thick horizontal line within box, median.
Open circles represent outliers and asterisks represent extremes. The p-value at gene-by-gene level is indicated in the left lower corner in each
graph. (B) Analysis of methylation frequencies for tumors with different chromosomal profiles. For definition of chromosomal groups, see Carén
et al [44]. CpG sites for SCNN1A and DUSP23 are shown. The highest methylation frequencies in SCNN1A are found in NB tumors with an
unfavorable chromosomal profile. Methylation of DUSP23 is almost mutually exclusive in MYCN-amplified NBs.
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Cell lines and tumor material
Expression analysis
The four NB cell lines SK-N-AS, SK-N-BE(2), SK-N-DZ
and IMR-32 were used for cDNA microarray analysis.
For conformation studies with real-time RT-PCR, these
four and another five NB cell lines (SK-N-SH, SK-N-FI,
SH-SY-5Y, Kelly and NB69) were used, as well as 43 NB
tumors and nine healthy control tissues (fetal brain,
fetal heart, fetal kidney, fetal spleen, fetal thymus, adre-
nal, colon, leukocytes and mammary gland; all from
Clontech Laboratories, Mountain View, CA). Ethical
permission was granted by the local ethics committee
(Karolinska Institutet and Karolinska University Hospi-
tal, registration number 03-736 and 2009/1369).
Methylation analysis
Fifty-nine NB tumors were analyzed with the Illumina
Human Methylation27 DNA analysis bead chips, together
Table 2 Methylation Δbeta values (methylation frequencies) between the outcome groups DOD and NED
Gene CpG site In CpG island Mean DOD (SD) Mean NED (SD) Δbeta value
SCNN1A cg18738906 yes 0.88 (0.21) 0.65 (0.27) 0.23***
cg26215727 no 0.47 (0.20) 0.31 (0.17) 0.16***
PRKCDBP cg05628549 yes 0.53 (0.28) 0.34 (0.26) 0.18*
cg16245261 yes 0.45 (0.34) 0.20 (0.23) 0.25**
cg18392783 yes 0.50 (0.32) 0.26 (0.24) 0.24**
cg18959478 yes 0.55 (0.31) 0.32 (0.27) 0.23**
KRT19 cg11462865 yes 0.65 (0.24) 0.43 (0.29) 0.22**
cg16585619 no 0.82 (0.09) 0.81 (0.06) 0.01
TGFBI cg00386408 yes 0.40 (0.24) 0.32 (0.23) 0.08
cg21034676 yes 0.28 (0.28) 0.23 (0.24) 0.04
POU2F2 cg21608489 yes 0.62 (0.22) 0.59 (0.20) 0.03
cg22054191 yes 0.22 (0.08) 0.24 (0.10) -0.02
DUSP23 cg10663017 yes 0.20 (0.25) 0.11 (0.16) 0.09
cg11104347 yes 0.17 (0.25) 0.10 (0.15) 0.08
DHRS3 cg01346152 yes 0.64 (0.30) 0.64 (0.26) 0.00
cg09229231 yes 0.03 (0.01) 0.03 (0.01) 0.00
COL1A2 cg18511007 yes 0.42 (0.27) 0.35 (0.25) 0.07
cg25300386 yes 0.37 (0.29) 0.32 (0.27) 0.05
DOD, dead of disease; NED, no evidence of disease; *p ≤ 0.05; **p < 0.01; ***p < 0.001; SD, standard deviation.
Table 3 Methylation Δbeta values (methylation frequencies) between various tumor characteristics
Gene CpG site INRG (M/L) 1p-del
a MNA
a 11q-del
a 17q-gain
a >18 m
SCNN1A cg18738906 0.33*** 0.15 0.21** 0.25*** 0.34*** 0.15*
cg26215727 0.15** 0.04 0.13* 0.17** 0.20*** 0.09
PRKCDBP cg05628549 0.09 -0.06 0.12 0.08 0.09 -0.10
cg16245261 0.17* 0.00 0.27*** 0.15 0.19* 0.01
cg18392783 0.12 -0.06 0.18** 0.10 0.12 -0.02
cg18959478 0.12 -0.06 0.16* 0.10 0.11 -0.04
KRT19 cg11462865 0.14 -0.01 0.19* 0.10 0.12 0.22**
cg16585619 0.01 -0.05* 0.07*** 0.04* 0.03 0.01
TGFBI cg00386408 0.05 -0.04 0.11 0.10 0.07 0.14*
cg21034676 0.04 -0.04 0.13 0.06 0.05 0.12
POU2F2 cg21608489 -0.08 -0.05 -0.08 -0.01 -0.04 -0.08
cg22054191 0.03 -0.03 -0.01 0.04 0.02 0.04
DUSP23 cg10663017 0.06 -0.10 0.27*** 0.21*** 0.16** 0.07
cg11104347 0.05 -0.13* 0.29*** 0.16** 0.13** 0.08
DHRS3 cg01346152 -0.13 -0.03 -0.20** -0.03 -0.08 -0.10
cg09229231 0.004* 0.00 0.00 0.00 0.00 0.00
COL1A2 cg18511007 0.07 0.00 0.05 0.07 -0.01 0.18**
cg25300386 0.02 -0.04 -0.02 0.02 -0.09 0.15*
M, metastatic; L, localized; 1p-del, 1p-deletion; MNA, MYCN amplification; 11q-del, 11q-deletion; m, months;
apresence of chromosomal aberration tested against
absence; *p ≤ 0.05; **p < 0.01; ***p < 0.001.
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controls and four NB cell lines, SK-N-AS, SK-N-BE(2), SK-
N-DZ and IMR-32 (additional file 8). Thirty-two of the
tumors used for expression analysis were included in the
methylation analysis. For bisulfite sequencing, nine NB cell
lines were used, together with control DNA from healthy
blood donors and one adrenal sample. Thirty of the tumors
analyzed with the methylation arrays were also used to ver-
ify the methylation status of some of the selected genes. In
addition, a methylated control sample and an unmethylated
control (EpiTect control DNA, Qiagen, Hilden, Germany),
as well as a 50/50 mixture of them, were used in the ampli-
fication of bisulfite-modified DNA, in order to control for
the unwanted selective amplification of methylated or
unmethylated templates during PCR amplification.
Drug treatments
Cells were treated with the demethylating agent 5-
Aza-2’-deoxycytidine (Sigma-Aldrich CO, St Louis, MO)
or the histone deacetylase inhibitor trichostatin A (TSA;
Sigma-Aldrich) or with a combinatorial treatment with
both agents as previously described [9]. A concentration
of 2 μM of 5-Aza-2’-deoxycytidine (5-Aza-dC) for 72
hours and 0.5 μM of TSA for 16 hours was used.
RNA extraction
Total RNA was extracted from cell lines and primary
tumors using the Totally RNA kit (Ambion, Austin, TX)
and was treated with DNA-free (Ambion), according to
the protocols of the supplier. RNA quality was assessed
using an Agilent 2100 Bioanalyzer (Agilent, Palo Alto,
CA) and by measuring absorbance with the Nanodrop
ND-1000 (NanoDrop Technologies, Wilmington, DE).
Expression microarray analysis
RNA was analyzed with the Human-6 v2 Expression
BeadChip (Illumina Inc., San Diego, CA) at AROS
Applied Biotechnology AS (Aros AB, Aarhus, Denmark),
according to the protocol provided by the supplier.
For the generation of biotin-labeled cRNA, the Illu-
mina TotalPrep RNA amplification kit (Ambion) was
used. In short, 300 ng of total RNA was reverse tran-
scribed and the first-strand cDNA was used to make
the second strand. The purified second-strand cDNA,
a l o n gw i t hb i o t i nU T P s ,w a st h e nt r a n s c r i b e din vitro
into biotinylated cRNA. Purified, labeled cRNA, 1.5 μg,
was hybridized to Sentrix Human-6 v2 expression Illu-
mina Beadchips for 16 h at 58°C, before being washed
and stained with streptavidin-Cy3. The bead chips
were then dried and scanned on the Illumina BeadAr-
ray Reader confocal scanner. Expression data gener-
ated by BeadStudio were exported and analyzed using
IlluminaGUI [40].
Analysis of DNA methylation
Illumina Human Methylation27 DNA analysis bead
chips were used to determine the methylation levels of
27,578 CpG sites. After bisulfite treatment of the DNA
samples, the cytosines in the CpG sites were genotyped
as C/T polymorphisms according to the manufacturer’s
protocol. The fluorescence signals were measured from
the BeadArrays using an Illumina BeadStation GX scan-
ner. The fluorescence data were then analyzed using the
BeadStudio software (Illumina). The software assigns a
score called a “beta value” to each CpG site, which cor-
responds to the ratio between the fluorescence signal
from the methylated allele (C) and the sum of the fluor-
escent signals of the methylated (C) and unmethylated
(T) alleles [41]. The array processing was performed by
the SNP Technology Platform in Uppsala (URL: http://
www.genotyping.se).
cDNA preparation and real-time RT-PCR
cDNA preparation was performed as previously described
[9]. Custom-designed TLDA cards containing 15 indivi-
dual assays were ordered from Applied Biosystems. 200 ng
of RNA converted into cDNA in a total volume of 100 μl
were loaded to each card according to the instructions of
the manufacturer. Each cDNA sample was analyzed in tri-
plicate. TLDA cards were run and analyzed by the ABI
PRISM
® 7900HT Sequence Detection System (SDS 2.2,
Applied Biosystems) according to manufacturer’s protocol
(Applied Biosystems). Calculations were performed using
the ΔCt relative quantification method. The thresholds
and baselines were set manually in SDS and Ct values
were extracted. All Ct values were normalized to the
housekeeping gene GUSB for each sample [9]. Samples
with no expression were set to a Ct value of 40. To evalu-
ate the agreement between the mRNA expression levels
and the DNA methylation levels, a Spearman correlation
coefficient was calculated for each gene. The delta Ct
values between groups were compared using Student’s
two-sided t-test. Fold change between groups was calcu-
lated from the 2^-delta Ct values.
DNA methylation analysis with bisulfite sequencing
CpG islands at the 5’ promoter region that included the
transcriptional start sites were identified using CpG
island searcher (URL: http://cpgislands.usc.edu) [42].
These regions, or parts of them, were amplified with
regular PCR or semi-nested/nested primers if needed.
Primers were designed with BiSearch [43]. Primer
sequences are available on request.
Methylation analysis was performed with tag-modified
bisulfite genomic sequencing [44]. Genomic DNA, 1 μg,
was modified with the EpiTect kit (Qiagen), according
to the protocol of the supplier. The modified DNA was
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fer, 0.5 mM dNTPs, 2.0-3.0 mM MgCl2,0 . 4μMo ff o r -
ward and reverse primers respectively and 1 unit of
HotStar Taq (Qiagen), in a total volume of 20 μl, with
or without the addition of Q-solution (Qiagen). Reac-
tions were denatured at 95°C for 10 min, followed by 20
cycles of 95°C for 45 sec, 10°C above annealing tempera-
ture with a decrease of half a degree per cycle for
45 sec, 68°C for 60 sec and 15-20 cycles of 95°C for 45
sec, annealing temperature for 45 sec, 68°C for 60 sec
and ending with a seven-minute extension at 68°C. The
specificity of products was inspected by agarose gel elec-
t r o p h o r e s i sb e f o r et h e yw e r ep u r i f i e du s i n gA g e n c o u r t
AMPure magnetic beads (Agencourt Bioscience Cor-
poration, Beverly, MA) using the Biomek NX pipetting
robot (Beckman Coulter) and eluted in distilled H2O.
Sequence PCR was performed using forward or reverse
primer with the ABI Prism BigDye™ cycle sequencing
Ready Reaction Kit v1.1 (Applied Biosystems). Sequence
PCR was run in 10 μl reactions under the following con-
ditions: 96°C for one minute, followed by 25 cycles of
96°C for 10 sec and 50°C for four minutes. Sequencing
products were purified using CleanSeq magnetic beads
(Agencourt) using the Biomek NX and re-suspended in
10 μl of High Dye formamide (Applied Biosystems). The
sequencing products were separated using gel electro-
phoresis on a 3730 DNA analyzer (Applied Biosystems)
and the output data were viewed and analyzed using
Sequence Analysis v5.2 (Applied Biosystems) and BiQ
Analyzer [45]. One methylated control sample, one
unmethylated control and one 50/50 mixture of methy-
lated and unmethylated controls were included in each
PCR to ensure that methylated and unmethylated tem-
plates were both equally amplified.
Methylation-specific PCR (MSP)
MSP was used to analyze the promoter region of
DHRS3. Primer sequences were taken from Furuta
et al [17]. The EpiTect MSP kit (Qiagen) was used to
amplify methylated and unmethylated templates in
separate reactions. The PCR products were separated
on a 2% agarose gel with GelRed (Biotium, Hayward,
CA) and visualized with UV light. Methylated and
unmethylated controls were used to check the specifi-
city of the assay.
Data analysis
The methylation frequencies of the genes grouped into
patients with a 5-year overall survival (OS) versus
patients dead of disease, INRG stage, as well as other
prognostic factors were compared with Student’st w o -
sided t-test. Considered as prognostic factors; five-year
OS, MYCN amplification, 1p deletion, 11q deletion, 17q
gain, INRG stage, age at diagnosis (cut-off at 18 months)
and gene methylation, were analyzed by logistic regres-
sion, both as single predictors and in multipredictor
models with one gene and one other predictor (Table 4).
Kaplan-Meier diagrams were used to illustrate the survi-
val of patients below and above median methylation
(Figure 4).
Table 4 Odds ratio for gene methylation, with and without adjustment for other prognostic factors
Unadjusted OR Adjusted OR for other prognostic factor
Gene CpG site INRG (M/L) MNA 11q-del >18 m
SCNN1A cg18738906 3.4** 2.2 3.0** 3.1** 3.1**
PRKCDBP cg16245261 2.5** 2.4* 2.3* 2.4* 2.9**
KRT19 cg11462865 2.5* 2.5* 2.2* 2.3* 2.1*
OR, odds ratio.
SCNN1A KRT19 PRKCDBP
Time (months) Time (months) Time (months)
Figure 4 Survival analysis. Methylation frequencies of the genes SCNN1A, KRT19 and PRKCDBP analyzed with Kaplan-Meier diagram. Patients are
separated by having a methylation frequency above (green line) and below the median (blue line) methylation beta value.
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Additional file 1: Venn diagrams of genes identified in the cell
treatment study. (A) Distribution of the top 100 probes (largest fold
change between untreated and treated cell lines), detected as up-
regulated in the study. Note that there are not always 100 probes in
each group, as there are cases in which more than one probe per gene
is identified in the top list. (B) Total number of genes up-regulated by
treatment and (C) down-regulated.
Additional file 2: Number of genes affected by treatments in at
least one cell line.
Additional file 3: List of genes upregulated by treatment in the
respective cell lines.
Additional file 4: Number of genes affected by treatment in the cell
lines and number of genes with a beta value of more than 0.75 in
the respective cell lines.
Additional file 5: The selected genes analyzed in this study.
Additional file 6: Fold change in gene expression after treatment
with 5-Aza-dC and/or TSA in the real-time RT-PCR and microarray
experiment.
Additional file 7: Fold change in gene expression between various
tumor characteristics.
Additional file 8: Patient data.
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